Compare Dr. Reddys with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 51.7 15.0 343.9% View Chart
P/BV x 5.8 3.3 177.4% View Chart
Dividend Yield % 0.4 0.3 126.5%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
AUROBINDO PHARMA
Mar-19
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875830 346.4%   
Low Rs1,888527 358.2%   
Sales per share (Unadj.) Rs930.2333.9 278.6%  
Earnings per share (Unadj.) Rs117.440.4 291.0%  
Cash flow per share (Unadj.) Rs185.851.8 358.9%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.80.4 227.9%  
Book value per share (Unadj.) Rs844.4237.1 356.2%  
Shares outstanding (eoy) m166.07585.91 28.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.62.0 126.0%   
Avg P/E ratio x20.316.8 120.6%  
P/CF ratio (eoy) x12.813.1 97.8%  
Price / Book Value ratio x2.82.9 98.5%  
Dividend payout %17.06.2 275.0%   
Avg Mkt Cap Rs m395,496397,569 99.5%   
No. of employees `00022.017.9 123.0%   
Total wages/salary Rs m33,56225,849 129.8%   
Avg. sales/employee Rs Th7,032.810,956.9 64.2%   
Avg. wages/employee Rs Th1,527.91,447.7 105.5%   
Avg. net profit/employee Rs Th887.71,324.3 67.0%   
INCOME DATA
Net Sales Rs m154,482195,636 79.0%  
Other income Rs m3,3751,553 217.3%   
Total revenues Rs m157,857197,189 80.1%   
Gross profit Rs m31,78239,519 80.4%  
Depreciation Rs m11,3486,680 169.9%   
Interest Rs m8892,626 33.9%   
Profit before tax Rs m22,92031,767 72.2%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m3,8587,269 53.1%   
Profit after tax Rs m19,50023,645 82.5%  
Gross profit margin %20.620.2 101.8%  
Effective tax rate %16.822.9 73.6%   
Net profit margin %12.612.1 104.4%  
BALANCE SHEET DATA
Current assets Rs m111,101153,645 72.3%   
Current liabilities Rs m58,973120,429 49.0%   
Net working cap to sales %33.717.0 198.7%  
Current ratio x1.91.3 147.7%  
Inventory Days Days79135 58.7%  
Debtors Days Days9464 147.9%  
Net fixed assets Rs m101,245103,909 97.4%   
Share capital Rs m830586 141.7%   
"Free" reserves Rs m139,406138,322 100.8%   
Net worth Rs m140,236138,908 101.0%   
Long term debt Rs m22,0001,800 1,222.6%   
Total assets Rs m224,656264,544 84.9%  
Interest coverage x26.813.1 204.5%   
Debt to equity ratio x0.20 1,211.0%  
Sales to assets ratio x0.70.7 93.0%   
Return on assets %9.19.9 91.4%  
Return on equity %13.917.0 81.7%  
Return on capital %14.923.8 62.7%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m88,67397,316 91.1%   
Fx outflow Rs m19,10440,589 47.1%   
Net fx Rs m69,56956,727 122.6%   
CASH FLOW
From Operations Rs m28,70416,220 177.0%  
From Investments Rs m-7,727-28,768 26.9%  
From Financial Activity Rs m-21,32619,191 -111.1%  
Net Cashflow Rs m-3146,656 -4.7%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA  SANOFI INDIA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 136 Points Lower; Telecom and Automobile Stocks Witness Selling(Closing)

Indian share markets witnessed volatile trading activity throughout the day and ended marginally lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

PSU Banks Will Move Up Again(Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

PSU Stocks Are Looking Positive Now(Fast Profits Daily)

Oct 19, 2020

Has the market changed its opinion on PSUs?

One Cycle that Defines Everything in Markets(Profit Hunter)

Oct 23, 2020

Know this cycle to boost your profits in the market.

Markets are Always Right?(The Honest Truth)

Oct 30, 2020

Ajit Dayal on why you shouldn't let your guard down as an investor.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 30, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS